26 May 2022 - The objective of the European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 (JA3) was to ...
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...
2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...
19 April 2022 - The establishment of health technology assessment has been an important topic in Europe for many years. ...
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...
20 February 2022 - For assessing cost effectiveness, health technology assessment organisations may use primary economic evaluations or systematic reviews of ...
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...
1 February 2022 - On Dec 15, 2021, the EU adopted a new regulation to harmonise health technology assessment of new ...
28 January 2022 - This article aims at describing the most relevant elements of the drug development process in the paediatric ...
28 January 2022 - The European Network for Health Technology Assessment (EUnetHTA) was established in 2006. During its final project phase ...